Ling Yuyang, Shen Yanqin, Xu Xudong, Yu Guocan
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Department of Nursing, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.
PLoS One. 2025 Feb 25;20(2):e0319175. doi: 10.1371/journal.pone.0319175. eCollection 2025.
Early, rapid and precise diagnosis of tuberculous pleurisy is difficult. Next-generation sequencing (NGS) has been used for the diagnosis of TB in some high-income countries. We completed the protocol of the study in order to better guide the systematic review and meta-analysis for evaluating the role of NGS in the diagnosis of tuberculous pleurisy, which was the purpose of the current study.
We designed and drafted this protocol as per the Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines. Three English databases (Cochrane Library, Embase and Medline via PubMed) and two Chinese databases (China National Knowledge Infrastructure and Wanfang Database) will be used to search for relevant studies. We followed the PICT principles to develop the eligibility criteria. Once the final compliant literature is identified, we will extract the valid information from the literature for statistical analysis. We will assess the quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. When there are more than 4 eligible studies, we will use Stata (version 15.0; Stata Corp., College Station, TX, the USA) with midas module to conduct the relevant meta-analysis and plot the relevant forest plots and curves. When there are less than 4 eligible studies, we will use Meta-DiSc (version 1.4) to perform the associated meta-analysis and plot the associated forest plots and curves. We will use the I2 statistic to assess heterogeneity between included studies. We will conduct meta-regression analysis, subgroup analysis and sensitivity analysis to explore possible sources of heterogeneity when significant heterogeneity exists.
PROSPERO Registration number: CRD42024568791.
结核性胸膜炎的早期、快速及准确诊断存在困难。在一些高收入国家，下一代测序（NGS）已用于结核病的诊断。我们完成了本研究方案，以便更好地指导系统评价和荟萃分析，以评估NGS在结核性胸膜炎诊断中的作用，这是本研究的目的。
我们根据系统评价与荟萃分析方案报告规范（PRISMA-P）指南设计并起草了本方案。将使用三个英文数据库（Cochrane图书馆、Embase和通过PubMed的Medline）和两个中文数据库（中国知网和万方数据库）检索相关研究。我们遵循PICT原则制定纳入标准。一旦确定最终符合要求的文献，我们将从文献中提取有效信息进行统计分析。我们将使用诊断准确性研究质量评估（QUADAS-2）工具评估纳入研究的质量。当有4项以上符合条件的研究时，我们将使用带有midas模块的Stata（版本15.0；美国德克萨斯州大学站市Stata公司）进行相关的荟萃分析，并绘制相关的森林图和曲线。当符合条件的研究少于4项时，我们将使用Meta-DiSc（版本1.4）进行相关的荟萃分析，并绘制相关的森林图和曲线。我们将使用I²统计量评估纳入研究之间的异质性。当存在显著异质性时，我们将进行meta回归分析、亚组分析和敏感性分析，以探索可能的异质性来源。
PROSPERO注册号：CRD42024568791。
